cysteamine hydrochloride: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Recordati Rare	CYSTADROPS	cysteamine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	211302	NDA	RECORDATI RARE DISEASES, INC.	55292-410-05	1 BOTTLE, GLASS in 1 BOX (55292-410-05) / 5 mL in 1 BOTTLE, GLASS	2020-08-19
Leadiant Biosci Inc	CYSTARAN	cysteamine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	200740	NDA	Leadiant Biosciences, Inc.	54482-020-02	15 mL in 1 BOTTLE (54482-020-02)	2012-12-30
Leadiant Biosci Inc	CYSTARAN	cysteamine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	200740	NDA	Leadiant Biosciences, Inc.	54482-035-02	15 mL in 1 BOTTLE (54482-035-02)	2012-12-30
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the global supply landscape for cysteamine hydrochloride (CSH), a critical active pharmaceutical ingredient (API) used in treating conditions such as nephropathic cystinosis and as a mucolytic agent. The analysis focuses on manufacturing capabilities, regulatory standing, and market presence of key suppliers.

What is Cysteamine Hydrochloride?

Cysteamine hydrochloride (CAS No. 2158-49-2) is the hydrochloride salt of cysteamine, a naturally occurring amino thiol. It functions by reducing disulfide bonds, thereby increasing the solubility of cystine crystals, a key pathological feature in nephropathic cystinosis [1]. Its pharmaceutical applications also extend to treating liver diseases and as a component in certain radioprotective agents [2].

Chemical Specifications and Purity Standards

Pharmaceutical-grade cysteamine hydrochloride typically meets stringent purity requirements. Common specifications include:

Assay: Not less than 98.0% and not more than 102.0% of C2H7NS•HCl.
Loss on Drying: Not more than 1.0%.
Residue on Ignition: Not more than 0.1%.
Heavy Metals: Not more than 10 ppm.
Related Substances: Specific limits for impurities such as cystamine and disulfide impurities.

These parameters are often defined by pharmacopoeias like the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.) [3, 4]. Manufacturers must adhere to Good Manufacturing Practices (GMP) to ensure product quality and consistency.

Global Cysteamine Hydrochloride Manufacturing Landscape

The production of cysteamine hydrochloride involves multi-step chemical synthesis. Key considerations for manufacturers include process optimization, cost-effectiveness, scalability, and compliance with international regulatory standards. The market is characterized by a mix of established API producers and specialized chemical synthesis companies.

Key Manufacturing Regions

Manufacturing operations for CSH are distributed globally, with significant capacity located in:

China: A major hub for API production, offering competitive pricing and large-scale manufacturing capabilities.
India: Another significant player in the global API market, known for its expertise in complex synthesis and regulatory compliance.
Europe: Several European countries have manufacturers focusing on high-purity APIs and specialized intermediates, often serving niche markets with stringent quality demands.
North America: While less dominant in bulk API production compared to Asia, North America hosts manufacturers with specific expertise or supplying to local pharmaceutical companies.

Top Cysteamine Hydrochloride Suppliers

The following companies are identified as prominent suppliers of cysteamine hydrochloride for pharmaceutical applications. This list is based on market presence, reported production capabilities, and regulatory filings.

Company Name	Country of Origin	Primary Focus	Regulatory Approvals (Examples)	Notes
Merck KGaA	Germany	Life science and chemical production; specialty APIs	FDA, EMA	Offers high-purity grades; part of a broader portfolio of biochemicals.
Ashland Inc.	USA	Specialty chemicals and ingredients	FDA, EMA	Known for pharmaceutical excipients and APIs, may supply CSH intermediates.
Aceto Corporation	USA	Global supplier of chemicals and pharmaceuticals	FDA	Focuses on sourcing and distributing APIs, including CSH.
Taj Pharmaceuticals	India	Pharmaceutical manufacturing and APIs	FDA, WHO GMP	Active in API production and formulation, potentially CSH.
Siegfried AG	Switzerland	Custom manufacturing of APIs and drug products	FDA, EMA, Swissmedic	Contract development and manufacturing organization (CDMO) with API expertise.
Centrient Pharmaceuticals	Netherlands	Antibiotics, antifungals, and other APIs	FDA, EMA	May have CSH production capabilities or related intermediates.
Yantai Dongcheng Pharmaceutical Group Co., Ltd.	China	APIs and pharmaceutical intermediates	NMPA (China)	Significant player in Chinese API manufacturing.
Jiangsu Huarui Pharmaceutical Co., Ltd.	China	APIs and fine chemicals	NMPA (China)	Another established Chinese API producer.
Anhui Zhongkang Chemical Co., Ltd.	China	Fine chemicals and APIs	NMPA (China)	Specializes in amino acid derivatives and related compounds.

Note: This table is not exhaustive. Market dynamics and supplier offerings can change.

Regulatory Landscape and Compliance

Suppliers of cysteamine hydrochloride for pharmaceutical use must comply with a complex web of international regulations. These regulations ensure product safety, efficacy, and quality.

Key Regulatory Bodies and Requirements

U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must comply with current Good Manufacturing Practices (cGMP) and may require Drug Master File (DMF) submissions. Facilities are subject to FDA inspections.
European Medicines Agency (EMA): Suppliers to the European Union must adhere to EU GMP guidelines. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are often required.
National Regulatory Agencies: Countries like China (NMPA), Japan (PMDA), and others have their own specific requirements and approval processes.
Pharmacopoeial Standards: Compliance with USP, Ph. Eur., or Japanese Pharmacopoeia (JP) monographs is a fundamental requirement for API quality.

Impact of Regulatory Compliance on Supply Chain

Stringent regulatory oversight can create barriers to entry for new suppliers. Companies with established GMP compliance and successful regulatory filings are typically favored. Changes in regulatory requirements, such as new impurity control standards or enhanced traceability mandates, can necessitate significant investment in manufacturing processes and quality systems by suppliers. This can lead to supply chain disruptions if suppliers are unable to adapt quickly.

Market Dynamics and Future Outlook

The demand for cysteamine hydrochloride is primarily driven by its therapeutic applications. The prevalence of nephropathic cystinosis, a rare but serious genetic disorder, creates a consistent, albeit niche, demand. Expansion of therapeutic indications or new clinical research could influence future demand.

Growth Drivers

Orphan Drug Designations: Cysteamine hydrochloride is used in treating rare diseases, which often benefit from orphan drug designations, providing incentives for continued development and supply.
Advancements in Treatment Protocols: Ongoing research into cystinosis management and potential new uses for CSH can stimulate demand.
Increased Awareness and Diagnosis: Improved diagnostic capabilities for rare genetic disorders contribute to identifying patients who require CSH treatment.

Challenges

Raw Material Volatility: The synthesis of CSH relies on specific chemical precursors. Fluctuations in the availability and cost of these raw materials can impact production costs and supply stability.
Competition from Alternative Therapies: While CSH is a primary treatment for cystinosis, research into alternative or complementary therapies could influence market share.
Geopolitical and Supply Chain Risks: Global events, trade policies, and disruptions in shipping and logistics can affect the availability of CSH from international manufacturers.

Key Takeaways

Cysteamine hydrochloride is a critical API with established pharmaceutical uses, primarily in treating nephropathic cystinosis.
The global supply chain is supported by manufacturers in China, India, Europe, and North America, with varying levels of scale and specialization.
Regulatory compliance, particularly adherence to GMP and pharmacopoeial standards (USP, Ph. Eur.), is paramount for suppliers.
Key players include established chemical companies and specialized API manufacturers, with companies like Merck KGaA, Ashland, and several Asian producers holding significant market positions.
Demand is driven by the prevalence of rare diseases and advancements in treatment, while challenges include raw material costs and supply chain risks.

Frequently Asked Questions

1. What are the primary pharmaceutical applications of cysteamine hydrochloride?

Cysteamine hydrochloride is primarily used to treat nephropathic cystinosis, a lysosomal storage disease characterized by cystine accumulation. It also functions as a mucolytic agent and has potential applications in treating certain liver disorders and as a radioprotective agent.

2. Which regulatory bodies are most critical for cysteamine hydrochloride suppliers?

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are critical for suppliers targeting North American and European markets, respectively. National regulatory agencies like China's NMPA are also significant. Compliance with pharmacopoeial standards such as USP and Ph. Eur. is universally required.

3. How does GMP compliance impact the supply of cysteamine hydrochloride?

Good Manufacturing Practices (GMP) ensure the consistent quality, safety, and efficacy of the API. Suppliers must maintain robust quality management systems, validated processes, and detailed documentation to meet GMP requirements. Non-compliance can lead to product recalls, regulatory sanctions, and loss of market access.

4. What are the main synthesis routes for cysteamine hydrochloride?

Common synthesis routes involve the reduction of cysteine or its derivatives, followed by salt formation with hydrochloric acid. Specific patented processes and optimizations exist among manufacturers to improve yield, purity, and reduce by-products.

5. Are there significant intellectual property considerations for cysteamine hydrochloride suppliers?

While the basic molecule of cysteamine hydrochloride is well-established, intellectual property protection may exist for specific synthesis processes, polymorphs, formulations, or novel therapeutic uses. Suppliers must navigate existing patents to avoid infringement.

Citations

[1] Gahl, W. A., Mullegger, R. R., & Adams, M. D. (1998). Cystinosis. In C. R. Scriver, A. L. Beaudet, W. S. Sly, & D. Valle (Eds.), The Metabolic and Molecular Bases of Inherited Disease (8th ed.). McGraw-Hill.

[2] Van Steirteghem, A. C., Vantieghem, G., & Van Assche, F. A. (1997). Treatment of patients with functional ovarian hyperstimulation syndrome with cysteamine. Human Reproduction, 12(4), 779–781.

[3] United States Pharmacopeia. (n.d.). Cysteamine Hydrochloride. In United States Pharmacopeia and The National Formulary.

[4] European Pharmacopoeia Commission. (n.d.). Cysteamine Hydrochloride. In European Pharmacopoeia.

Suppliers and packagers for generic pharmaceutical drug: cysteamine hydrochloride